PostEra, NeuroLucent to partner on identifying small-molecule therapeutics for Alzheimer’s
PostEra, a UK-based biotech company, has entered into a collaboration with NeuroLucent, a US company focused on developing drugs for the treatment of Alzheimer’s disease ... Read More
UCB signs $2bn worth deal with Roche for AD drug candidate UCB0107
Belgian pharma company UCB has signed a global exclusive license deal worth up to $2 billion for its Alzheimer's Disease drug candidate (AD drug candidate) ... Read More
NeuroBo, Gemphire merger wrapped up to form neurodegenerative disease company
NeuroBo Pharmaceuticals, a Boston-based clinical-stage pharma company, has wrapped up its previously announced merger with Gemphire Therapeutics, a Michigan-based clinical-stage biopharma company focused on developing ... Read More
AgeneBio enrolls first patient in phase 3 trial for AGB101 in MCI due to Alzheimer’s Disease
AgeneBio, a leading biopharmaceutical company specialising in central nervous system (CNS) disorders, has announced the enrolment of the first patient in its pivotal phase 3 ... Read More
Breakthrough Alzheimer’s treatments on the horizon: New drugs and potential vaccine
Global Health Update — Promising developments in the fight against Alzheimer's disease could significantly alter the landscape of treatment and prevention within the next decade. ... Read More